Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Cancer research. 1999 59:5830-5. (IHC-P; Mouse, Human) [PubMed:10582706]
Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. Duyndam MC, Hulscher TM, Fontijn D, Pinedo HM, Boven E. The Journal of biological chemistry. 2001 276:48066-76. (WB; Human) [PubMed:11641398]
4
Phosphorylation by mitogen-activated protein kinase mediates the hypoxia-induced turnover of the TAL1/SCL transcription factor in endothelial cells. Tang T, Arbiser JL, Brandt SJ. The Journal of biological chemistry. 2002 277:18365-72. (WB; Human) [PubMed:11904294]
5
Effect of hypoxia on human seminoma cells. Fujii T, Otsuki T, Moriya T, Sakaguchi H, Kurebayashi J, Yata K, Uno M, Kobayashi T, Kimura T, Jo Y, Kinugawa K, Furukawa Y, Morioka M, Ueki A, Tanaka H. International journal of oncology. 2002 20:955-62. (ICC; Human) [PubMed:11956589]
6
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH. Cancer cell. 2002 1:459-68. (IHC; Human) [PubMed:12124175]
7
Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, Lewis CE. The American journal of pathology. 2003 163:1233-43. (IHC; Human) [PubMed:14507633] [PMC:PMC1868302]
8
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R. Proceedings of the National Academy of Sciences of the United States of America. 2003 100:12337-42. (IHC-P; Mouse) [PubMed:14526102] [PMC:PMC218759]
9
Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. The Journal of biological chemistry. 2005 280:41928-39. [PubMed:16223732]
10
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS. Cancer research. 2006 66:3639-48. [PubMed:16585189]
11
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B. Molecular and cellular biology. 2006 26:5336-47. [PubMed:16809770] [PMC:PMC1592699]
12
Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced cell death. An HJ, Maeng O, Kang KH, Lee JO, Kim YS, Paik SG, Lee H. The Journal of biological chemistry. 2006 281:33939-48. [PubMed:16954213]
13
Peroxisomal localization of hypoxia-inducible factors and hypoxia-inducible factor regulatory hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation. Khan Z, Michalopoulos GK, Stolz DB. The American journal of pathology. 2006 169:1251-69. (ICC, IHC-P; Rat) [PubMed:17003483] [PMC:PMC1698853]
14
Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Ramanathan M, Pinhal-Enfield G, Hao I, Leibovich SJ. Molecular biology of the cell. 2007 18:14-23. (WB; Mouse) [PubMed:17065555] [PMC:PMC1751314]
15
BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Tracy K, Dibling BC, Spike BT, Knabb JR, Schumacker P, Macleod KF. Molecular and cellular biology. 2007 27:6229-42. [PubMed:17576813] [PMC:PMC1952167]
16
Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H. Breast cancer research and treatment. 2008 110:465-75. [PubMed:17805961]
17
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 13:7388-93. [PubMed:18094421]
18
Acute ethanol exposure disrupts VEGF receptor cell signaling in endothelial cells. Radek KA, Kovacs EJ, Gallo RL, DiPietro LA. American journal of physiology. Heart and circulatory physiology. 2008 295:H174-84. [PubMed:18469146] [PMC:PMC2494747]
19
Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Rosenberger C, Rosen S, Shina A, Frei U, Eckardt KU, Flippin LA, Arend M, Klaus SJ, Heyman SN. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2008 23:3472-8. [PubMed:18515655]
20
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Stagg J, Sharkey J, Pommey S, Young R, Takeda K, Yagita H, Johnstone RW, Smyth MJ. Proceedings of the National Academy of Sciences of the United States of America. 2008 105:16254-9. [PubMed:18838682] [PMC:PMC2570981]
21
ADAMTS1 is a unique hypoxic early response gene expressed by endothelial cells. Hatipoglu OF, Hirohata S, Cilek MZ, Ogawa H, Miyoshi T, Obika M, Demircan K, Shinohata R, Kusachi S, Ninomiya Y. The Journal of biological chemistry. 2009 284:16325-33. [PubMed:19349275] [PMC:PMC2713541]
22
Satellite cell-mediated angiogenesis in vitro coincides with a functional hypoxia-inducible factor pathway. Rhoads RP, Johnson RM, Rathbone CR, Liu X, Temm-Grove C, Sheehan SM, Hoying JB, Allen RE. American journal of physiology. Cell physiology. 2009 296:C1321-8. [PubMed:19386789] [PMC:PMC2692418]
23
MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Aubert S, Fauquette V, Hmon B, Lepoivre R, Briez N, Bernard D, Van Seuningen I, Leroy X, Perrais M. Cancer research. 2009 69:5707-15. [PubMed:19549898]
24
Miltenberger blood group antigen type III (Mi.III) enhances the expression of band 3. Hsu K, Chi N, Gucek M, Van Eyk JE, Cole RN, Lin M, Foster DB. Blood. 2009 114:1919-28. [PubMed:19564639] [PMC:PMC2738576]
25
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK. The Journal of biological chemistry. 2009 284:29065-76. [PubMed:19679656] [PMC:PMC2781452]
26
Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 28:3746-53. (IHC; Human) [PubMed:20625125]
27
Biologic correlates of F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N. Lung cancer (Amsterdam, Netherlands). 2011 71:144-50. (IHC; Human) [PubMed:20646779]
28
Xanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}. Gibbings S, Elkins ND, Fitzgerald H, Tiao J, Weyman ME, Shibao G, Fini MA, Wright RM. The Journal of biological chemistry. 2011 286:961-75. [PubMed:21059659] [PMC:PMC3020781]
29
Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. Hlscher M, Silter M, Krull S, von Ahlen M, Hesse A, Schwartz P, Wielockx B, Breier G, Katschinski DM, Zieseniss A. The Journal of biological chemistry. 2011 286:11185-94. [PubMed:21270129] [PMC:PMC3064173]
30
Hypoxia-inducible factor 1 regulates the expression of the mitochondrial ATPase inhibitor protein (IF1) in rat liver. Huang LJ, Chuang IC, Dong HP, Yang RC. Shock (Augusta, Ga.). 2011 36:90-6. (WB; Rat) [PubMed:21412184]
31
Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011 52:705-11. [PubMed:21498541]
32
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP, Haluska P. Gynecologic oncology. 2011 122:116-20. (IHC; Human) [PubMed:21514634] [PMC:PMC3104066]
33
Hypoxia inducible factor-1 directly induces the expression of receptor activator of nuclear factor-B ligand in periodontal ligament fibroblasts. Park HJ, Baek KH, Lee HL, Kwon A, Hwang HR, Qadir AS, Woo KM, Ryoo HM, Baek JH. Molecules and cells. 2011 31:573-8. (WB; Human) [PubMed:21533547]
34
RETRACTED ARTICLE: Relationship between (18)F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer. Schneider C, Krischke G, Rascher W, Gassmann M, Trollmann R. Annals of nuclear medicine. 2012 26:288. [PubMed:21656105]
35
Systemic hypoxia differentially affects neurogenesis during early mouse brain maturation. Schneider C, Krischke G, Rascher W, Gassmann M, Trollmann R. Brain & development. 2012 34:261-73. [PubMed:21824737]
36
Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A. Breast cancer research and treatment. 2012 133:179-88. (IHC; Human) [PubMed:21877141]
37
Methionine sulfoxide reductase A: Structure, function and role in ocular pathology. Sreekumar PG, Hinton DR, Kannan R. World journal of biological chemistry. 2011 2:184-92. [PubMed:21909460] [PMC:PMC3163237]
38
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Medical oncology (Northwood, London, England). 2012 29:1663-72. (IHC; Human) [PubMed:21948461]
39
MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. Kaira K, Okumura T, Nakagawa K, Ohde Y, Takahashi T, Murakami H, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N. Pathology oncology research : POR. 2012 18:439-47. (IHC; Human) [PubMed:21964914]
40
18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. Kaira K, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Hayashi I, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. European journal of radiology. 2012 81:2423-9. (IHC; Human) [PubMed:22055682]
41
Mild hypoxia-induced cardiomyocyte hypertrophy via up-regulation of HIF-1-mediated TRPC signalling. Chu W, Wan L, Zhao D, Qu X, Cai F, Huo R, Wang N, Zhu J, Zhang C, Zheng F, Cai R, Dong D, Lu Y, Yang B. Journal of cellular and molecular medicine. 2012 16:2022-34. (ICC, WB; Rat) [PubMed:22129453]
42
Unfavourable consequences of chronic cardiac HIF-1 stabilization. Hlscher M, Schfer K, Krull S, Farhat K, Hesse A, Silter M, Lin Y, Pichler BJ, Thistlethwaite P, El-Armouche A, Maier LS, Katschinski DM, Zieseniss A. Cardiovascular research. 2012 94:77-86. [PubMed:22258630]
43
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. European journal of cancer (Oxford, England : 1990). 2012 48:1244-54. [PubMed:22330319]
44
The Role of Hypoxia-Inducible Factor-1 and -2 in Androgen Insensitive Prostate Cancer Cells. Kaira K, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Hayashi I, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. Urologic oncology. 2012 (WB; Human) [PubMed:22537539]
45
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ. Human pathology. 2012 43:2129-37. (IHC; Human) [PubMed:22542128]
46
The prognostic value of expression of HIF1, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L, Miralbell R. Radiation oncology (London, England). 2012 7:66. (IHC; Human) [PubMed:22546016] [PMC:PMC3432017]
47
Hypoxia modulation of peroxisome proliferator-activated receptors (PPARs) in human glioblastoma stem cells. Implications for therapy. Galzio R, Cristiano L, Fidoamore A, Cifone MG, Benedetti E, Cinque B, Menghini P, Raysi Dehcordi S, Ippoliti R, Giordano A, Cimini A. Journal of cellular biochemistry. 2012 113:3342-52. (ICC, Flo; Human) [PubMed:22644833]
48
Identification of a molecular signature underlying inhibition of mammary carcinoma growth by dietary N-3 fatty acids. Jiang W, Zhu Z, McGinley JN, El Bayoumy K, Manni A, Thompson HJ. Cancer research. 2012 72:3795-806. (WB; Rat) [PubMed:22651929]
49
Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer. Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Okui T, Hu GF, Sasaki A. Oral oncology. 2012 48:1120-7. (IHC, WB; Human) [PubMed:22694909]
50
Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1 and HIF2 in tumor-associated fibroblasts and human breast cancer cells. Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Tanowitz HB, Pestell RG, Sotgia F, Lisanti MP. Cell cycle (Georgetown, Tex.). 2012 11:3280-9. (ICC, WB; Human) [PubMed:22894905] [PMC:PMC3466527]
51
The role of hypoxic-inducible factor (HIF1) and aldolaseC protein in endometrial carcinogenesis: a retrospective study of 279 patients. Mhawech-Fauceglia P, Wang D, Samrao D, Menesses T, Godoy H, Ough F, Lele S, Liu S, Pejovic T. BMJ open. 2012 2: (IHC; Human) [PubMed:22923632] [PMC:PMC3432840]
52
Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Zhao Y, Xiong X, Jia L, Sun Y. Cell death & disease. 2012 3:e386. (WB; Human) [PubMed:22951983] [PMC:PMC3461362]
53
Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease. Ding A, Kalaignanasundaram P, Ricardo SD, Abdelkader A, Witting PK, Broughton BR, Kim HB, Wyse BF, Phillips JK, Evans RG. Clinical and experimental pharmacology & physiology. 2012 39:917-29. (ICC, IHC; Rat) [PubMed:23006058]
54
Perlecan Domain V induces VEGf secretion in brain endothelial cells through integrin 51 and ERK-dependent signaling pathways. Clarke DN, Al Ahmad A, Lee B, Parham C, Auckland L, Fertala A, Kahle M, Shaw CS, Roberts J, Bix GJ. PloS one. 2012 7:e45257. (WB; Mouse) [PubMed:23028886] [PMC:PMC3444475]
55
MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Brenner RM, Slayden OD. International journal of urology : official journal of the Japanese Urological Association. 2012 (IHC; Human) [PubMed:23050614]
56
Upregulation of VEGF expression is associated with accumulation of HIF-1 in the skin of nave scleroderma patients. Brenner RM, Slayden OD. Modern rheumatology / the Japan Rheumatism Association. 2012 (IHC; Human) [PubMed:23096096]
57
Molecular and functional aspects of menstruation in the macaque. Brenner RM, Slayden OD. Reviews in endocrine & metabolic disorders. 2012 13:309-18. (IHC; Avian) [PubMed:23108498] [PMC:PMC3523117]
HIF1A Antibody, ARNT-interacting protein Antibody, ARNT interacting protein Antibody, BHLHe78 Antibody, HIF1 Alpha Antibody, Hypoxia-inducible factor1alpha Antibody, HIF-1A Antibody, HIF1 Antibody, MOP1 Antibody, Member of PAS superfamily 1 Antibody, PASD8 Antibody, HIF-1-alpha Antibody, HIF-1alpha Antibody, HIF1-ALPHA Antibody, Member of PAS protein 1 Antibody
Hypoxia-inducible factor-1 (HIF1) is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential rol.
PDF Spec Sheet
Technical Help
